Key facts
- New Frontier Bio’s last known valuation is $8.0M.
- It has raised $14.7M across 2 recorded rounds; the latest was Early Stage VC ($8.9M) in Sep 2022.
- Notable investors include Ambrosia Investments, Taihill Venture.
- New Frontier Bio has filed 2 Form Ds with the SEC since 2022, most recently Jun 2024 ($309K sold to 6 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for New Frontier Bio
Funding rounds
2 roundsAbout New Frontier Bio
Developer of consumer health products designed to reverse the signs of aging and promote natural health and lifespan on a cellular level. The company's products include skin health and supplements based on a natural compound for skin longevity, enabling consumers to improve their quality of life by addressing aging.
- Sector
- Healthcare
- HQ
- Beverly, MA, United States
- Founded
- 2020
- Employees
- 7
- Website
- newfrontierbio.com/
- Ownership
- Privately Held (backing)
New Frontier Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in New Frontier Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on New Frontier Bio in its N-PORT filings yet. We sweep new filings monthly.